BACKGROUND: Poor adherence to antiretroviral therapy contributes to pharmacokinetic variability and is the major determinant of virological failure. However, measuring treatment adherence is difficult, especially in children. We investigated the relationship between plasma lopinavir concentrations, pretreatment characteristics and viral load >400 copies/ml. METHODS: A total of 237 HIV-infected children aged 4-42 months on lopinavir/ritonavir oral solution were studied prospectively and followed for up to 52 weeks. Viral load and lopinavir concentration were measured at clinic visits 12, 24, 36 and 52 weeks after starting treatment. Cox multiple failure events models were used to estimate the crude and adjusted effect of lopinavir concentrations on the hazard of viral load >400 copies/ml. RESULTS: The median (IQR) pretreatment CD4(+) T-lymphocyte percentage was 18.80% (12.70-25.35) and 53% of children had a pretreatment viral load >750,000 copies/ml. The median (IQR) weight-for-age and height-for-age z-scores were -2.17 (-3.35--2.84) and -3.34 (-4.57--3.41), respectively. Median (IQR) lopinavir concentrations were 8.00 mg/l (4.11-12.42) at median (IQR) 3.50 h (2.67-4.25) after the dose. The hazard of viral load >400 copies/ml was increased with lopinavir concentrations <1 mg/l versus ≥1 mg/l (adjusted hazard ratio 2.3 [95% CI 1.63, 3.26]) and lower height-for-age z-scores. CONCLUSIONS: Low lopinavir concentrations (<1 mg/l) are associated with viraemia in children. This measure could be used as a proxy for adherence and to determine which children are more likely to fail.
BACKGROUND: Poor adherence to antiretroviral therapy contributes to pharmacokinetic variability and is the major determinant of virological failure. However, measuring treatment adherence is difficult, especially in children. We investigated the relationship between plasma lopinavir concentrations, pretreatment characteristics and viral load >400 copies/ml. METHODS: A total of 237 HIV-infectedchildren aged 4-42 months on lopinavir/ritonavir oral solution were studied prospectively and followed for up to 52 weeks. Viral load and lopinavir concentration were measured at clinic visits 12, 24, 36 and 52 weeks after starting treatment. Cox multiple failure events models were used to estimate the crude and adjusted effect of lopinavir concentrations on the hazard of viral load >400 copies/ml. RESULTS: The median (IQR) pretreatment CD4(+) T-lymphocyte percentage was 18.80% (12.70-25.35) and 53% of children had a pretreatment viral load >750,000 copies/ml. The median (IQR) weight-for-age and height-for-age z-scores were -2.17 (-3.35--2.84) and -3.34 (-4.57--3.41), respectively. Median (IQR) lopinavir concentrations were 8.00 mg/l (4.11-12.42) at median (IQR) 3.50 h (2.67-4.25) after the dose. The hazard of viral load >400 copies/ml was increased with lopinavir concentrations <1 mg/l versus ≥1 mg/l (adjusted hazard ratio 2.3 [95% CI 1.63, 3.26]) and lower height-for-age z-scores. CONCLUSIONS: Low lopinavir concentrations (<1 mg/l) are associated with viraemia in children. This measure could be used as a proxy for adherence and to determine which children are more likely to fail.
Authors: Gert Uves van Zyl; Thijs E van Mens; Helen McIlleron; Michele Zeier; Jean B Nachega; Eric Decloedt; Carolina Malavazzi; Peter Smith; Yong Huang; Lize van der Merwe; Monica Gandhi; Gary Maartens Journal: J Acquir Immune Defic Syndr Date: 2011-04 Impact factor: 3.731
Authors: Salvador Resino; José Maria Bellón; José Tomás Ramos; Maria Luisa Navarro; Pablo Martín-Fontelos; Esther Cabrero; Maria Angeles Muñoz-Fernández Journal: Pediatr Infect Dis J Date: 2004-10 Impact factor: 2.129
Authors: Paul Palumbo; Jane C Lindsey; Michael D Hughes; Mark F Cotton; Raziya Bobat; Tammy Meyers; Mutsawashe Bwakura-Dangarembizi; Benjamin H Chi; Philippa Musoke; Portia Kamthunzi; Werner Schimana; Lynette Purdue; Susan H Eshleman; Elaine J Abrams; Linda Millar; Elizabeth Petzold; Lynne M Mofenson; Patrick Jean-Philippe; Avy Violari Journal: N Engl J Med Date: 2010-10-14 Impact factor: 91.245
Authors: Ellen Gould Chadwick; Jorge Pinto; Ram Yogev; Carmelita G Alvero; Michael D Hughes; Paul Palumbo; Brian Robbins; Rohan Hazra; Leslie Serchuck; Barbara E Heckman; Lynette Purdue; Renee Browning; Katherine Luzuriaga; John Rodman; Edmund Capparelli Journal: Pediatr Infect Dis J Date: 2009-03 Impact factor: 2.129
Authors: Mark M Kabue; Adeodata Kekitiinwa; Albert Maganda; Jan M Risser; Wenyaw Chan; Mark W Kline Journal: AIDS Patient Care STDS Date: 2008-03 Impact factor: 5.078
Authors: Yuan Ren; James J C Nuttall; Claire Egbers; Brian S Eley; Tammy M Meyers; Peter J Smith; Gary Maartens; Helen M McIlleron Journal: J Acquir Immune Defic Syndr Date: 2008-04-15 Impact factor: 3.731
Authors: Hylke Waalewijn; Anna Turkova; Natella Rakhmanina; Tim R Cressey; Martina Penazzato; Angela Colbers; David M Burger Journal: Ther Drug Monit Date: 2019-08 Impact factor: 3.681
Authors: Jose R Castillo-Mancilla; Johnathan A Edwards; Jaysingh Brijkumar; Mahomed-Yunus Moosa; Yuan Zhao; Igho Ofotokun; Brent A Johnson; Mitchell H Lee; Selvan Pillay; Melendhran Pillay; Pravi Moodley; Daniel R Kuritzkes; Henry Sunpath; Lane R Bushman; Lucas Ellison; Peter L Anderson; Vincent C Marconi Journal: J Int AIDS Soc Date: 2021-12 Impact factor: 5.396
Authors: Henri Gautier Ouedraogo; Alberto Matteelli; Giorgia Sulis; Tegwinde Rebeca Compaore; Serge Diagbouga; Simon Tiendrebeogo; Alberto Roggi; Kadari Cisse; Pier Francesco Giorgetti; Paola Villani; Lassana Sangare; Jacques Simpore; Mario Regazzi; Seni Kouanda Journal: Ann Clin Microbiol Antimicrob Date: 2020-01-22 Impact factor: 3.944
Authors: Tom G Jacobs; Elin M Svensson; Victor Musiime; Pablo Rojo; Kelly E Dooley; Helen McIlleron; Rob E Aarnoutse; David M Burger; Anna Turkova; Angela Colbers Journal: J Antimicrob Chemother Date: 2020-12-01 Impact factor: 5.790